Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1864 participants.

Also called NCT02607865

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,864 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02607865
  • EudraCT 2015-001351-71
Main results
  • Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial JAMA, 2019-04-16 DOI, PubMed 30903796, PMC6484814 Not in the PMC Open Access subset.
Other papers using this trial's data
  • Efficacy and safety of oral semaglutide in Japanese patients with type 2 diabetes: A post hoc subgroup analysis of the PIONEER 1, 3, 4 and 8 trials Diabetes, obesity & metabolism, 2021-12 DOI, PubMed 34472698, PMC9293331 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Brazil, France, Germany, India, Israel, Japan, Mexico, Romania, Russia, South Africa, Türkiye, Ukraine, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02607865. Randomized; double masking; primary purpose treatment. Start 2016-02-15 (actual); primary completion 2017-02-14 (actual). Results posted on 2020-02-27.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
Acronym
PIONEER 3
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
semaglutide
Intervention (Drug)
sitagliptin
Intervention (Drug)
placebo
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct02607865
Content hash
a6ec3fee5c2d28b0b4c0e666e37754ee500e38f9cb3660480885e2514b468878